Esophageal Cancer Radiation Management

Scope and treatment selection

Radiation management should be determined by clinical TNM stage, resectability, tumor location, histology, performance status, comorbidity, and the feasibility of surgery; the evidence supplied here is heterogeneous and includes randomized trials, meta-analyses, prospective single-arm data, retrospective cohorts, and diagnostic studies ^{[1]A1a[4]A1b[6]A1b[9]B2b[12]B2b[18]B3b}. The recommendations below therefore distinguish curative endoscopic, trimodality, definitive, postoperative, salvage, and investigational approaches rather than assigning one radiation strategy to every patient within a stage group ^{[1]A1a[4]A1b[7]B2a[12]B2b[14]C4}.

Stage I and superficial disease

For T1aN0M0 squamous cell carcinoma, endoscopic resection (ER) can provide definitive local treatment when the lesion is completely removed with a negative margin and lacks lymphovascular invasion; in the prospective selective-treatment study, patients meeting these criteria received no additional treatment ^[12]B2b. After ER, prophylactic chemoradiotherapy (CRT) using 41.4 Gy to locoregional lymph nodes was used for selected patients with T1b (SM1–2) N0M0 disease with a negative margin or T1a disease with lymphovascular invasion, although the supplied abstract does not provide the complete outcome data or all treatment-group results ^[12]B2b.

Esophagectomy remains a standard option for stage I esophageal squamous cell carcinoma, while selective CRT after ER is a prospective alternative for appropriately selected superficial tumors ^[12]B2b. Definitive CRT is also a curative option for cT1bN0M0 esophageal squamous cell carcinoma, but residual local disease or recurrence after an apparent complete response can occur; retrospective endoscopic findings may help identify patients at increased risk of non-radical cure ^[16]C4.

The role of intraluminal brachytherapy as a curative boost in stage I squamous cell carcinoma remains uncertain. A systematic review found that the optimal radiation method for early disease has not been established and that the effects of brachytherapy on local control and survival remain controversial ^[7]B2a. Thus, brachytherapy should not be considered routine stage I treatment on the basis of the supplied evidence ^[7]B2a.

For superficial disease after noncurative endoscopic submucosal dissection (ESD), esophagectomy is described as the standard adjuvant treatment, but retrospective data also support adjuvant CRT as a potentially effective alternative in selected patients; the comparison included 60 patients, of whom 34 received CRT and 26 underwent surgery ^[17]B3b.

Stage II–III and resectable locally advanced disease

For resectable, nonmetastatic locally advanced disease, neoadjuvant CRT followed by esophagectomy is an established curative strategy in the cited clinical literature ^{[18]B3b[19]C4}. In a meta-analysis of three randomized trials involving 375 patients, neoadjuvant CRT significantly increased R0 resection and pathologic complete response rates compared with neoadjuvant chemotherapy alone, but did not significantly improve 3- or 5-year progression-free survival or overall survival ^[1]A1a.

The CROSS regimen described in routine practice consisted of five weekly courses of carboplatin and paclitaxel with concurrent external-beam radiation delivered as 23 fractions of 1.8 Gy, followed by surgery ^[18]B3b. The supplied evidence does not establish that one neoadjuvant regimen is universally preferred across histologies, tumor sites, or healthcare systems ^{[1]A1a[18]B3b}. Patients should be reassessed after neoadjuvant therapy before proceeding to esophagectomy, because a retrospective cohort found that 16.8% of patients scheduled for neoadjuvant treatment and surgery did not ultimately undergo resection ^[19]C4.

The optimal neoadjuvant radiation dose remains unsettled. A large retrospective National Cancer Database analysis compared 41.4, 45, and 50.4 Gy in patients receiving neoadjuvant CRT for nonmetastatic disease and evaluated overall survival, downstaging, and perioperative mortality; because this was not a randomized comparison, it does not define a universally superior dose ^[84]C.

Routine adjuvant chemotherapy after neoadjuvant CRT and esophagectomy should not be assumed to improve outcomes. In a retrospective ESCC cohort of 382 patients, only 69 received adjuvant chemotherapy; reported 5-year overall and disease-free survival were 47.1% and 42.6%, respectively, and adjuvant chemotherapy did not improve overall survival in the reported analysis ^[15]B3b.

Unresectable locally advanced disease

Definitive CRT is described as the current standard for locally advanced unresectable esophageal carcinoma, particularly thoracic squamous cell carcinoma ^[4]A1b. JCOG1510/TRIANgLE was designed to test induction docetaxel, cisplatin, and 5-fluorouracil followed by conversion surgery or definitive CRT versus definitive CRT alone; the planned phase III study enrolled 230 patients, with overall survival as the primary endpoint, so the supplied trial description is not evidence of superiority ^[4]A1b.

For unresectable disease treated with definitive CRT, overall survival remains the definitive clinical endpoint. A later correlation analysis was specifically designed to evaluate whether event-free survival can serve as a surrogate for overall survival in trials of definitive CRT, but the supplied abstract does not report its results ^[3]A1a.

Cervical esophageal squamous cell carcinoma may be treated definitively when surgery is unsuitable or not selected. In a retrospective series of 30 patients treated with three-dimensional conformal radiotherapy, the median gross-tumor and involved-node dose was 60 Gy; 26 patients received concurrent chemotherapy and 26 received elective nodal irradiation to cervical and upper mediastinal regions at a median 40 Gy ^[56]C4.

Postoperative, recurrent, and anatomically borderline disease

Adjuvant concurrent CRT after radical resection has been evaluated in patients with stage IIB–IVA disease. In a retrospective series of 125 patients, 122 received more than 50 Gy, but only 52 completed more than 5 weeks of combined treatment, indicating substantial treatment-intensity variation and limiting interpretation of efficacy ^[6]A1b.

For locoregional recurrence after surgery, salvage RT or concurrent CRT may provide a potentially curative or disease-controlling option in selected patients without prohibitive toxicity. A retrospective study of 147 patients used 60 Gy in 20 fractions for RT alone and 60–70 Gy in 30–35 fractions for concurrent CRT; the study evaluated clinical outcomes but does not establish a randomized standard ^[14]C4.

Concurrent cervical-node metastasis in thoracic esophageal or gastroesophageal-junction cancer represents a border zone between locoregional and distant disease. A Dutch nationwide cohort evaluated definitive CRT, neoadjuvant therapy followed by surgery, and chemotherapy with or without limited RT of ≤30 Gy, but the supplied abstract does not provide comparative survival results; treatment should therefore be individualized in a multidisciplinary setting ^[9]B2b.

Response assessment and treatment adaptation

Contrast-enhanced CT is used for diagnosis and initial staging of esophageal squamous cell carcinoma, but conventional CT alone is insufficient to predict early recurrence reliably; CT radiomics and clinical-feature models have been investigated for recurrence prediction after trimodality therapy ^[2]A1b. MRI-based methods have also been studied for early response assessment during neoadjuvant therapy or concurrent CRT, but a 2024 meta-analysis concluded that the clinical role remains under exploration ^[5]B2a. Interim 18F-FDG PET metabolic response during neoadjuvant CRT has been systematically evaluated for predicting pathologic response, progression-free survival, and overall survival ^[8]B2a. Dynamic contrast-enhanced MRI response criteria have been retrospectively studied for identifying pathologic complete response after neoadjuvant CRT, but these data are not sufficient to replace pathological assessment or establish omission of surgery ^[13]B3b.

Role and treatment intent

EBRT is an established component of definitive management for patients with esophageal cancer who are not surgical candidates, including treatment delivered alone or with concurrent chemotherapy. ^[21]B2a Contemporary EBRT is commonly delivered with three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), volumetric-modulated arc therapy (VMAT), and, in selected centers, proton or carbon-ion therapy. ^{[26]D5[29]B3b[31]B3b} Definitive treatment should be individualized according to stage, tumor location and extent, nodal-risk pattern, performance status, comorbidity, nutritional reserve, and the feasibility of systemic therapy; these factors were associated with outcome in retrospective cohorts, although the cited studies do not establish a single optimal regimen. ^{[24]B3b[27]D5[30]B3b[31]B3b}

Target volumes: involved-field versus elective nodal irradiation

The principal field-design controversy is whether to irradiate only the gross tumor and clinically involved nodes (involved-field irradiation, IFI) or to include clinically uninvolved regional nodal stations (elective nodal irradiation, ENI). ^{[21]B2a[28]B3b} A systematic review and meta-analysis specifically evaluated definitive radiotherapy or chemoradiotherapy comparing IFI with ENI, with overall survival and radiotherapy-related adverse events as principal outcomes. ^[21]B2a The available evidence supports considering IFI as a reasonable field strategy when limiting treatment volume and toxicity is important, but the analysis addresses an area in which target-size selection remains uncertain and should not be interpreted as proof that ENI is universally inferior. ^[21]B2a

A large retrospective IMRT series included 924 patients, of whom 272 received ENI and 652 received IFI; propensity-score matching was used to compare the groups. ^[28]B3b These data provide substantial observational support for individualized field selection, but residual confounding remains possible because treatment allocation was not randomized. ^[28]B3b ENI may remain appropriate when the anticipated risk of microscopic nodal disease is high, whereas IFI may be favored when reducing irradiated normal tissue and treatment burden is a priority; this clinical distinction is consistent with the comparative question addressed by the meta-analysis and retrospective study. ^{[21]B2a[28]B3b}

Dose, fractionation, and dose escalation

Standard-dose IMRT in one large retrospective comparison was 60 Gy in 30 fractions, using 2 Gy per fraction, delivered once daily on 5 days per week. ^[23]C4 The same study compared standard-dose IMRT with simultaneous integrated boost (SIB)-IMRT in patients with locally advanced esophageal squamous cell carcinoma after propensity-score matching, but its retrospective design limits causal interpretation. ^[23]C4 A separate propensity-score study evaluated selective dose escalation to the local tumor using SIB-IMRT in 302 patients; median overall survival for the entire cohort was 30.0 months, and median disease-free survival was 21.3 months. ^[27]D5 Chemotherapy, cTNM stage, and dose per fraction were examined as prognostic variables in multivariable analysis, indicating that dose should not be considered independently of stage and systemic treatment. ^[27]D5

For early-stage disease, a multicenter retrospective study evaluated 196 patients with T1-2N0M0 esophageal squamous cell carcinoma treated definitively; 78 received radiochemotherapy and 118 received radiotherapy alone. ^[31]B3b The cohort included 96 patients treated with 3DCRT and 100 with IMRT, with median planning target volume and gross tumor volume doses of 60 Gy and a median follow-up of 59.2 months. ^[31]B3b These results support definitive EBRT as a potential treatment approach in carefully selected early-stage patients, while not establishing equivalence between radiotherapy alone and combined-modality therapy. ^[31]B3b

IMRT, postoperative treatment, and clinical outcomes

IMRT has been used both definitively and postoperatively. ^{[22]B3b[24]B3b[28]B3b[30]B3b} In a retrospective series of 228 patients with resected thoracic esophageal squamous cell carcinoma receiving postoperative IMRT, the median total dose was 60 Gy; reported overall survival at 1, 3, and 5 years was 89.9%, 56.7%, and 45.1%, respectively. ^[22]B3b A separate cohort of 1,637 patients treated with IMRT reported 1-, 3-, and 5-year overall survival of 65.9%, 34.2%, and 27.0%, and progression-free survival of 45.8%, 25.0%, and 18.5%, respectively. ^[30]B3b These series are retrospective and should be interpreted as outcome benchmarks rather than direct comparisons of competing EBRT techniques. ^{[22]B3b[30]B3b}

Among 103 patients with squamous cell carcinoma treated with definitive IMRT alone, investigators analyzed prognostic factors across stage I–IVA disease, reflecting real-world use of RT without concurrent chemotherapy in selected patients. ^[24]B3b In elderly patients aged over 70 years, definitive concurrent chemoradiotherapy using S-1 with IMRT or VMAT was evaluated retrospectively in 80 patients; pretreatment hematologic and inflammatory indicators were assessed for prognostic relevance. ^[29]B3b Treatment selection and tolerance in older adults should therefore incorporate geriatric fitness, comorbidity, nutritional status, and the feasibility of chemotherapy rather than age alone. ^[29]B3b

Advanced planning and particle therapy

Charged-particle therapy, including proton beam and carbon-ion radiotherapy, has been investigated because the Bragg peak can reduce dose to adjacent normal tissues compared with photon therapy; however, the cited review describes clinical results and dosimetric rationale rather than definitive randomized superiority for survival or toxicity. ^[26]D5 Nationwide Japanese claims data from April 2017 through March 2023 were used to describe real-world radiotherapy trends, including adoption of IMRT and changing fractionation schedules; definitive radiotherapy was operationally defined as 25–35 treatment days in patients without distant metastasis. ^[85]D

Practical synthesis

EBRT planning should prioritize adequate coverage of the primary tumor and clinically relevant nodes while minimizing exposure of organs at risk. ^{[21]B2a[26]D5[28]B3b} IMRT or VMAT is particularly useful when conformality and normal-tissue sparing are clinically important, whereas SIB or selective dose escalation should be considered investigational or selectively applied because supporting evidence is predominantly retrospective. ^{[23]C4[27]D5[29]B3b} Nutritional and functional assessment is important: sarcopenia, measured using total psoas area on cross-sectional CT, was specifically investigated as a predictor of severe acute toxicity, pathologic response, and survival in patients receiving neoadjuvant chemoradiation followed by surgery. ^[25]B3b

Clinical role and evidence base

Brachytherapy is an intraluminal radiation technique that can deliver a localized dose to an esophageal tumor and has been investigated as definitive therapy, as a boost after external-beam radiotherapy (EBRT), during reirradiation, and for palliation. ^[32]C4 Its role in early-stage disease remains uncertain because the optimal radiotherapy approach for stage I esophageal cancer has not been established and the effects of brachytherapy on local control and survival remain controversial. ^[7]B2a The highest-level evidence supplied here is a systematic review of brachytherapy used with curative intent for stage I esophageal squamous cell carcinoma; palliative studies were excluded, and overall survival and disease-free survival were the primary outcomes, with locoregional outcomes assessed as secondary endpoints. ^[7]B2a

Stage I and superficial disease

The systematic review specifically evaluated brachytherapy as a boost strategy in stage I esophageal squamous cell carcinoma. ^[7]B2a However, the supplied evidence does not provide pooled survival, disease-free survival, local-control, toxicity, or comparative-effect estimates; therefore, no survival advantage or routine indication for brachytherapy can be established from the available abstract information. ^[7]B2a

A retrospective study of 123 patients with superficial esophageal cancer provides a clinically relevant non-brachytherapy comparator. ^[33]B3b All patients received definitive EBRT with concurrent systemic chemotherapy and no intracavitary brachytherapy; elective nodal irradiation was not performed. ^[33]B3b The prescribed dose was 60 Gy in 30 fractions to the planning treatment volume. ^[33]B3b The cohort had a median age of 66 years, included 106 men and 17 women, and consisted almost entirely of squamous cell carcinoma cases (122 of 123). ^[33]B3b Twenty-seven patients had cT1a disease and 96 had cT1b disease; tumors were located in the cervical, upper thoracic, middle thoracic, and lower thoracic esophagus. ^[33]B3b Because this study did not include brachytherapy, it cannot determine whether a brachytherapy boost improves outcomes over definitive chemoradiotherapy. ^[33]B3b

Retrospective institutional experience

A single-center retrospective series evaluated all consecutive patients treated with high-dose-rate esophageal brachytherapy at Institut Gustave Roussy from 1992 through 2018. ^[32]C4 Ninety patients were treated for four indications: exclusive brachytherapy in 7 patients, boost after EBRT in 41, reirradiation in 36, and palliation in 6. ^[32]C4 The most frequently used regimens were 3 × 5 Gy for boost treatment and 6 × 5 Gy for exclusive treatment or reirradiation. ^[32]C4 Dose was prescribed at the applicator surface or at 5 mm. ^[32]C4 The abstract reports that, by the end of follow-up, 50% of patients had experienced a stated outcome, but the supplied excerpt does not identify that outcome or provide indication-specific survival, local-control, or toxicity results. ^[32]C4 Consequently, this series supports the feasibility of several clinical applications but does not establish comparative efficacy or a preferred regimen. ^[32]C4

Technique, selection, and limitations

Potential clinical use should be individualized according to treatment intent, prior EBRT, tumor location and extent, residual or recurrent disease, and the feasibility of safe applicator placement; the references supplied here do not define validated selection criteria or dose constraints. ^[7]B2a[32]C4 The evidence is limited by the retrospective design of the institutional series, its long treatment period, heterogeneous indications, and the absence of the detailed outcome data in the supplied abstract. ^[32]C4 The systematic review addresses curative treatment but does not, in the supplied information, provide a definitive recommendation for routine brachytherapy. ^[7]B2a

An experimental dosimetric study examined 125I seed-loaded self-expanding coated esophageal stents with different seed spacings, diameters, lengths, and seed activities. ^[35]D5 The investigators used a cylindrical organic-glass and paraffin model, CT imaging, and a treatment-planning system to characterize cumulative dose distributions. ^[35]D5 These data may inform dosimetric planning for radioactive stents, but the study was a model-based dosimetric investigation and does not demonstrate clinical tumor control, survival, safety, or palliation. ^[35]D5

The supplied report on esophageal schwannomas concerns imaging and preoperative diagnosis of a rare benign esophageal tumor treated surgically and provides no evidence relevant to malignant esophageal brachytherapy. ^[34]D5

Practical interpretation

Brachytherapy may be considered a specialized, individualized option—most plausibly as a boost after EBRT or for selected reirradiation cases—rather than a universally established component of treatment. ^[7]B2a[32]C4 For superficial disease, definitive chemoradiotherapy without intracavitary brachytherapy has been reported using 60 Gy in 30 fractions, but this experience cannot resolve whether adding brachytherapy improves outcomes. ^[33]B3b Referral to a multidisciplinary team with expertise in endoluminal radiation is appropriate when brachytherapy is contemplated, particularly in previously irradiated patients, although the supplied references do not provide formal consensus criteria. ^[7]B2a[32]C4

Overview

Concurrent chemoradiation (CRT) is used in neoadjuvant, definitive, selective post-endoscopic, postoperative, and salvage settings for esophageal cancer. The appropriate strategy depends on resectability, tumor stage, histology, patient fitness, and whether surgery is planned. Evidence is heterogeneous: randomized evidence supports improved pathologic and surgical endpoints with neoadjuvant CRT compared with neoadjuvant chemotherapy alone, whereas survival advantages have not been consistently demonstrated. ^[1]A1a

Neoadjuvant CRT followed by surgery

A meta-analysis of 3 randomized controlled trials involving 375 patients—189 assigned to neoadjuvant CRT and 186 to neoadjuvant chemotherapy—found that adding radiotherapy significantly increased the R0 resection rate and pathologic complete response (pCR) rate. ^[1]A1a However, the analysis found no significant difference in 3- or 5-year progression-free survival or 3- or 5-year overall survival. ^[1]A1a These findings support neoadjuvant CRT as an effective method for tumor downstaging and improving resection quality, but they do not establish a universal long-term survival benefit over chemotherapy alone. ^[1]A1a

The CROSS regimen is a commonly implemented neoadjuvant CRT approach consisting of 5 weekly courses of carboplatin and paclitaxel—carboplatin area under the curve 2 and paclitaxel 50 mg/m²—with concurrent external-beam radiotherapy delivered as 23 fractions of 1.8 Gy. ^[18]B3b In a real-world institutional cohort of patients with resectable, nonmetastatic esophageal cancer, this regimen was followed by planned resection; the study evaluated clinical outcomes in routine practice rather than providing randomized comparative evidence. ^[18]B3b

Treatment delivery must account for nutritional and functional decline. In an exploratory analysis of patients receiving neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma, weight loss during treatment was evaluated in relation to postoperative infectious complications and prognosis, highlighting weight trajectory as a clinically relevant perioperative variable. ^[37]B2b Patients scheduled for neoadjuvant therapy may also fail to reach esophagectomy; in one retrospective series, 16.8% of patients did not undergo planned resection after starting neoadjuvant treatment. ^[19]C4

Definitive CRT

For locally advanced unresectable thoracic esophageal squamous cell carcinoma, definitive CRT with cisplatin plus 5-fluorouracil was described as the current standard in the design of the Japanese phase III JCOG1510/TRIANgLE trial. ^[4]A1b That trial was designed to test whether induction docetaxel, cisplatin, and 5-fluorouracil followed by conversion surgery or definitive CRT improves overall survival compared with definitive CRT alone; the cited publication is a trial-design report and does not establish the comparative efficacy of the experimental strategy. ^[4]A1b

Definitive CRT is also a curative option for selected cT1bN0M0 esophageal squamous cell carcinomas, although local residual or recurrent disease can occur after complete remission. ^[16]C4 Endoscopic features associated with non-radical cure have been investigated retrospectively, but the study size was limited to 40 patients, so these findings should not replace multidisciplinary assessment. ^[16]C4

Early disease and post-endoscopic treatment

A prospective study evaluated selective CRT after endoscopic resection in T1b (SM1-2) N0M0 thoracic esophageal squamous cell carcinoma. ^[12]B2b Patients with favorable pathology after endoscopic resection could receive no additional treatment, whereas patients with higher-risk findings were assigned to additional treatment pathways, including prophylactic CRT using 41.4 Gy to locoregional lymph nodes. ^[12]B2b Retrospective comparisons have also examined CRT versus esophagectomy after noncurative endoscopic submucosal dissection for superficial squamous cell carcinoma; these data are nonrandomized and should be interpreted as comparative observational evidence. ^[17]B3b

Dose-escalated postoperative radiotherapy after endoscopic submucosal dissection has been studied in selected superficial cancers with muscularis-mucosa involvement plus lymphovascular invasion or other high-risk features. ^[40]B3b In that retrospective series, definitive-dose radiotherapy ranged from 50 to 61.2 Gy, with or without chemotherapy, rather than the 40–41.4 Gy prophylactic CRT doses reported in prior approaches. ^[40]B3b

Adjuvant and salvage CRT

Postoperative concurrent CRT has been evaluated after radical resection in stage IIB–IVA esophageal carcinoma. ^[6]A1b In one retrospective series, 97.6% of patients received more than 50 Gy, but only 41.6% received more than 5 weeks of chemoradiotherapy; 58.4% received only 1–4 weeks, illustrating treatment-completion limitations. ^[6]A1b These data describe tolerability and short-term outcomes but do not provide randomized evidence establishing routine postoperative CRT.

For locoregional recurrence after surgery, salvage radiotherapy or concurrent chemoradiotherapy is used selectively. ^[14]C4 The reported regimens included 60 Gy in 20 fractions for radiotherapy alone and 60–70 Gy in 30–35 fractions for concurrent CRT. ^[14]C4 Adjuvant chemotherapy after neoadjuvant CRT and surgery did not improve overall survival in a retrospective ESCC cohort, so routine postoperative chemotherapy after trimodality treatment remains unsupported by that analysis. ^[15]B3b

Response assessment and related evidence

Interim 18F-FDG PET has been studied as a prognostic and predictive tool during neoadjuvant CRT, with research focusing on changes in standardized uptake value and associations with pathologic response, progression-free survival, and overall survival. ^[8]B2a MRI, including diffusion- and contrast-enhanced techniques, has likewise been evaluated for early response assessment during neoadjuvant therapy or concurrent CRT, but the cited evidence emphasizes ongoing methodological variation. ^[5]B2a A retrospective DCE-MRI study proposed five qualitative response grades to identify pCR after neoadjuvant CRT; such criteria remain investigational. ^[13]B3b

Evidence concerning EFS as a surrogate for OS in definitive CRT for unresectable locally advanced disease is still being evaluated, and its validity in this setting has not been established. ^[3]A1a Pembrolizumab plus chemotherapy is relevant to first-line advanced esophageal cancer, but the cited KEYNOTE-590 follow-up does not evaluate concurrent CRT and should not be extrapolated to radiotherapy-based management. ^[36]A1b Similarly, studies of Xiaoaiping plus chemotherapy address systemic treatment rather than concurrent CRT. ^[38]A1b

Scope and treatment selection

Adjuvant and palliative radiotherapy (RT) should be selected according to resection status, recurrence pattern, symptom burden, prior treatment, expected survival, and the feasibility of systemic therapy. The available evidence supplied for this section is predominantly retrospective, single-institution, or population-based observational evidence; therefore, treatment associations should not be interpreted as proof of benefit over alternative strategies.^{[6]A1b[9]B2b[32]C4[41]B3b[46]C4[50]D5[52]D5}

Cervical lymph-node metastasis in otherwise resectable thoracic esophageal or gastroesophageal-junction cancer represents a clinical boundary between locoregional and distant disease. A Dutch nationwide cohort specifically compared definitive chemoradiotherapy, neoadjuvant treatment followed by surgery, and chemotherapy with or without limited RT (≤30 Gy) in this population and evaluated overall survival, but the supplied abstract does not provide the comparative survival estimates.^[9]B2b Treatment should therefore be individualized through multidisciplinary review rather than determined solely by the cervical-node location.^[9]B2b

Postoperative and post-endoscopic RT

Evidence for postoperative concurrent chemoradiotherapy remains nonrandomized. In a retrospective series of 125 patients with stage IIB–IVA disease treated after radical resection, 122 patients received >50 Gy (97.6%). Only 52 patients completed more than 5 weeks of concurrent chemotherapy and RT, whereas 73 received 1–4 weeks, indicating substantial difficulty completing combined treatment; the study assessed tolerability, short-term efficacy, and survival.^[6]A1b

A separate retrospective analysis of 195 patients with curatively resected thoracic esophageal squamous-cell carcinoma compared no adjuvant treatment, chemotherapy, RT, and chemoradiotherapy. The median RT dose was 45.0 Gy (range, 34.8–59.4 Gy), and outcomes examined included overall survival, disease-free survival, and locoregional recurrence.^[50]D5 Because treatment assignment was retrospective and the supplied evidence does not report the adjusted comparative results, these data support postoperative RT or chemoradiotherapy as consideration in selected high-risk patients rather than as a universal standard.^[50]D5

For patients undergoing non-radical resection of locally advanced esophageal squamous-cell carcinoma, a retrospective Chinese study evaluated planned neoadjuvant RT in 33 patients and concurrent chemoradiotherapy in 119 patients. Median follow-up was 29.8 months, and 101 patients survived longer than 3 years; the study analyzed survival and prognostic factors, but the supplied abstract does not establish a randomized comparison or identify a preferred regimen.^[46]C4

After endoscopic submucosal dissection (ESD) for superficial clinical T1N0M0 cancer, prophylactic chemoradiation using 40–41.4 Gy has been reported to produce favorable outcomes but does not completely prevent regional lymph-node metastasis. A retrospective series of 44 patients instead examined dose-escalated, definitive-dose RT of 50–61.2 Gy, with or without chemotherapy, after ESD in patients with pathological muscularis-mucosa involvement with lymphovascular invasion or other high-risk superficial disease. This approach should be regarded as selected adjuvant treatment rather than routine therapy because the evidence is retrospective.^[40]B3b

Recurrent and metastatic disease

Recurrence after potentially curative surgery commonly requires individualized salvage planning. A retrospective series of patients recurring after neoadjuvant chemo(radio)therapy and radical esophagectomy, treated between 1994 and 2015, emphasized that potentially curative salvage strategies are available only in limited circumstances and evaluated survival according to dissemination pattern and prognostic factors.^[41]B3b RT may therefore be considered for localized or symptomatic recurrence when anatomy, prior dose, and performance status permit, while disseminated recurrence generally requires integration with systemic therapy.^{[41]B3b[51]D5}

For metastatic esophagogastric cancer, palliative RT to the primary tumor has been studied after initial chemotherapy in patients with well-controlled metastatic disease. Among 132 patients receiving palliative chemotherapy, 97 had responding or stable disease after 3 months; 53 subsequently received primary-tumor palliative RT and 44 continued chemotherapy alone. The study assessed time to local progression and other treatment-related outcomes, but its retrospective design limits causal interpretation.^[52]D5 Real-world systemic-treatment data from 2,204 patients with synchronous metastatic esophagogastric cancer demonstrate substantial heterogeneity in first-line monotherapy, doublet, triplet, and trastuzumab-containing strategies; this study was not designed to determine the value of RT.^[51]D5

Brachytherapy and symptom-directed palliation

High-dose-rate esophageal brachytherapy has been used as exclusive treatment, an external-beam boost, reirradiation, or palliation. In a retrospective Institut Gustave Roussy series of 90 patients treated from 1992–2018, the most frequent schedules were 3 × 5 Gy for boost treatment and 6 × 5 Gy for exclusive treatment or reirradiation, prescribed at the applicator surface or 5 mm depth. The evidence supports feasibility in carefully selected patients but does not define a universally preferred dose or demonstrate superiority over external-beam RT.^[32]C4

Stents, RT, and endoscopic palliation

Self-expanding metallic stents (SEMS) remain an established means of relieving malignant dysphagia or fistula when rapid mechanical palliation is required, but the interaction between SEMS and RT requires caution. In a retrospective cohort of 323 patients, predominantly with squamous-cell carcinoma (79.6%), investigators evaluated adverse events in patients who had received or would receive RT; the study was specifically motivated by uncertainty regarding SEMS safety with RT.^[42]C4 Another retrospective series of 192 patients undergoing 236 SEMS procedures found significant dysphagia-score improvement within 1 week and 1 month, including patients receiving additional palliative treatment.^[45]B3b

Stenting in the cervical esophagus or hypopharynx is technically challenging and may be poorly tolerated. A retrospective review of 69 patients evaluated cervical-esophageal stenting according to whether the hypopharynx was involved.^[43]C4 In patients with prior RT, a low-radial-force Niti-S stent produced major adverse-event rates of 6.3% versus 5.9% without prior RT (p=0.95) in a retrospective comparison of 83 patients, although these findings should not be generalized to every stent design or clinical setting.^[53]D5 A prospective pilot study also evaluated a multisegmented, fully covered SEMS with antimigration features against historical controls, focusing on technical success, clinical efficacy, migration, restenosis, and adverse events.^[54]D5

Photodynamic therapy can be combined with EBRT or SEMS for recurrent obstruction. In 20 patients, dysphagia improved in 90% at 4 weeks; recurrent dysphagia led to stent insertion after a mean of 63 days, and major complications occurred in 10%.^[47]B2b Rare skeletal-muscle metastases were identified in 4 of 205 PET/CT-evaluated patients, with one apparent case subsequently attributed to a second primary pancreatic cancer; PET/CT findings should therefore be confirmed when they would alter RT intent.^[44]C4

Scope and clinical framing

Toxicity after esophageal-cancer radiotherapy (RT) is influenced by treatment intent, concurrent systemic therapy, prior irradiation, tumor location, airway involvement, surgery, and the use of an esophageal stent. The available evidence supplied here is heterogeneous and is dominated by retrospective series, technical reviews, and selected prospective studies; therefore, reported rates should not be generalized across treatment settings. ^{[10]A1b[23]C4[32]C4[42]C4[53]D5[56]C4}

Acute toxicity during and shortly after RT

Acute esophageal mucosal injury commonly presents clinically as worsening dysphagia and impaired oral intake, although the supplied studies do not provide a uniform grading system or pooled incidence. Risk is particularly relevant when RT is combined with chemotherapy: a retrospective target-trial emulation of 432 adults aged ≥70 years compared definitive RT alone with concurrent chemoradiotherapy (CCRT), evaluating treatment completion, grade ≥3 toxicity, and unplanned readmission within 90 days. The study was designed to address the balance between disease control and tolerability in older adults, but the supplied abstract does not report the comparative outcome estimates. ^[10]A1b

In a large retrospective comparison of simultaneous integrated-boost intensity-modulated RT and standard-dose intensity-modulated RT for locally advanced esophageal squamous cell carcinoma, standard treatment was 60 Gy in 30 fractions; the investigators specifically assessed safety alongside efficacy. The evidence base consisted of 109 SIB-IMRT patients and 266 standard-dose IMRT patients selected from a larger cohort of 1,748 definitive-CCRT patients, with propensity-score matching used to reduce baseline imbalance. ^[23]C4

Definitive three-dimensional conformal RT for cervical esophageal squamous cell carcinoma was evaluated in 30 patients, with a median gross-tumor and involved-node dose of 60 Gy; 26 patients received concurrent chemotherapy and elective nodal irradiation. This anatomic site requires particular attention to swallowing, laryngeal, and airway symptoms, although the supplied abstract does not provide detailed acute-toxicity frequencies. ^[56]C4

Airway-involved tumors represent a high-risk toxicity setting. In a retrospective series of 83 patients, 97.6% had squamous histology and all received taxane–platinum induction chemotherapy before reassessment for possible radical therapy. The rationale was to reduce the morbidity and treatment-related mortality associated with immediate radical treatment, particularly the risk of treatment-induced tracheoesophageal fistula (TEF). ^[61]C4

Airway, fistula, and postoperative complications

Esophageal tumors abutting or invading the tracheobronchial tree can cause TEF or bronchoesophageal fistula, aspiration, respiratory infection, and potentially fatal airway compromise. In a retrospective study of 335 patients receiving self-expandable metallic stents (SEMS), 37 patients (11.0%) developed SEMS-induced esophagorespiratory fistula, with a median interval of 129 days after stent placement. ^[57]B3b A separate 20-year case-series review examined 15 patients with TEF or bronchoesophageal fistula and evaluated open surgery, airway or esophageal stenting, and gastrostomy/jejunostomy; the supplied abstract indicates that these fistulas are uncommon but potentially life-threatening, but does not provide treatment-specific outcome estimates. ^[58]C4

Primary tracheobronchial necrosis after esophagectomy is a distinct postoperative complication defined as necrosis without anastomotic leakage or another cervical or mediastinal abscess. A nationwide Japanese questionnaire study collected data from 6,370 esophagectomy patients treated at 67 institutions between 2010 and 2019 and classified severity as grade 1 mucosal necrosis, grade 2 transmural bronchial-wall necrosis without fistula or perforation, and higher grades involving structural complications. ^[55]B3b Postoperative imaging is essential when complications are suspected after Ivor-Lewis esophagectomy because altered anatomy complicates interpretation; anastomotic leak, gastric-conduit necrosis, and pleuropulmonary complications are among the most serious complications. ^[63]D5 Minimally invasive surgery may reduce blood loss and postoperative pain and accelerate recovery, but the reviewed experience did not demonstrate consistent reductions in early postoperative complications or improvements in long-term outcomes. ^[64]D5

Stents, re-irradiation, and late toxicity

SEMS placement in an irradiated esophagus requires caution because RT may alter tissue integrity and healing. In a retrospective study of 323 patients with malignant stenosis or fistula, investigators evaluated whether prior or subsequent RT affected SEMS adverse events; squamous carcinoma accounted for 79.6% of tumors and partially covered stents predominated. ^[42]C4 Conversely, a low-radial-force Niti-S SEMS series included 83 patients, including 32 with prior RT and 51 without prior RT. Major adverse events occurred in 6.3% of the prior-RT group versus 5.9% of the non-RT group, a nonsignificant difference (P=0.95), supporting—but not proving—the feasibility of carefully selected low-radial-force stenting after RT. ^[53]D5 In another retrospective series, SEMS insertion improved dysphagia within 1 week and 1 month; outcomes were compared in patients with and without additional palliative treatment. ^[45]B3b

Late local toxicity includes persistent or recurrent dysphagia, benign stricture, ulceration, bleeding, perforation, and fistula. High-dose-rate esophageal brachytherapy was retrospectively assessed in 90 patients treated for exclusive therapy, external-beam RT boost, re-irradiation, or palliation. Common schedules included 3 × 5 Gy as a boost and 6 × 5 Gy for exclusive treatment or re-irradiation, prescribed at the applicator surface or 5 mm depth; at follow-up, 50% of patients had experienced the reported late clinical event in the supplied abstract, although the event and denominator details are incomplete. ^[32]C4 For refractory benign strictures, a prospective, nonrandomized, single-arm, eight-institution trial evaluated a biodegradable stent after at least 5 dilations or at least 1 radial incision and cutting procedure in patients with dysphagia score ≥2 and an endoscope unable to pass; the primary endpoint was safety and efficacy. ^[60]B2b

Non-esophageal radiation injury and diagnostic pitfalls

Focal hepatic FDG uptake after neoadjuvant chemoradiotherapy may represent radiation-induced liver injury rather than metastasis. A retrospective study and literature review emphasized that this finding can mimic liver metastases on post-treatment FDG-PET/CT and lead to overstaging; interval metastases are detected in almost 10% of patients undergoing restaging, making correlation with treatment fields and imaging morphology important. ^[59]C4

A rare but clinically important toxicity concern is marked radiosensitivity in Fanconi anemia. A case report described a patient with synchronous esophageal and tongue cancers who received 30 Gy to the esophageal mass and later 27 Gy to the tongue surgical bed, with no additional treatment and no evidence of disease at 7 months; the case illustrates the need for individualized risk assessment rather than establishing a standard dose or safety threshold. ^[65]C4

Outcome measures and interpretation

Overall survival (OS) remains the reference outcome for trials evaluating locally advanced or unresectable esophageal cancer, although its assessment requires prolonged follow-up and can delay treatment evaluation ^[3]A1a. Event-free survival (EFS) is being investigated as a surrogate for OS in definitive chemoradiotherapy (dCRT), but its validity in unresectable disease has required specific trial-level evaluation ^[3]A1a. In resectable disease, recurrence-free or disease-free survival (RFS/DFS) has also been assessed as a potential surrogate for OS; a 2025 meta-analysis identified 11 eligible studies, with pooled hazard ratios of 0.90 for OS and 0.87 for RFS/DFS, although the reported correlation was not sufficient to make RFS/DFS interchangeable with OS in every clinical setting ^[76]B2a.

Definitive and multimodality treatment outcomes

The evidence supplied here does not provide a new pooled OS or local-control estimate for contemporary dCRT, but it emphasizes that EFS should not automatically be treated as a validated replacement for OS until trial-level surrogacy is demonstrated in this specific setting ^[3]A1a. Treatment selection for resectable thoracic esophageal or gastroesophageal-junction cancer with concurrent cervical lymph-node metastasis remains uncertain in Western populations; a Dutch nationwide cohort compared dCRT, neoadjuvant treatment followed by surgery, and chemotherapy with or without limited radiotherapy of ≤30 Gy, reflecting the clinically important distinction between definitive and limited radiation approaches ^[9]B2b.

For advanced disease, systemic therapy can materially affect outcomes that are often reported alongside radiation strategies. In the Japanese subgroup of KEYNOTE-590, five-year follow-up evaluated first-line pembrolizumab plus cisplatin/5-fluorouracil against chemotherapy alone in previously untreated advanced esophageal cancer, using OS, progression-free survival (PFS), objective response rate (ORR), and safety as outcomes; the supplied abstract states that earlier follow-up showed numerically improved OS and PFS with pembrolizumab, but does not provide the subgroup’s final numerical estimates ^[36]A1b. In a real-world cohort of 184 patients receiving second-line nivolumab for unresectable or metastatic disease, the response rate among 128 patients with measurable lesions was 23%, disease control for the full cohort was 45%, and grade ≥3 adverse events occurred in 14%, with no treatment-related deaths reported ^[70]B2b. These results are systemic-therapy outcomes and should not be attributed to radiation alone ^{[36]A1b[70]B2b}.

Response assessment and prognostic tools

Imaging-based response assessment may help identify patients likely to benefit from neoadjuvant chemoradiotherapy or concurrent chemoradiotherapy, but it should complement—not replace—clinical staging and pathologic assessment. A systematic review and meta-analysis evaluated MRI parameters, including diffusion-weighted imaging and apparent diffusion coefficient (ADC), for predicting response to neoadjuvant therapy in esophageal cancer; the review specifically compared baseline ADC, changes in ADC, and treatment response, while noting variation among sequences and study methods ^[69]B2a. A separate meta-analysis examined MRI for early response prediction during neoadjuvant therapy or concurrent chemoradiotherapy and concluded that the field remained heterogeneous and required further validation ^[5]B2a.

Interim 18F-FDG PET has likewise been studied as a prognostic and predictive marker during neoadjuvant chemoradiotherapy. The meta-analysis assessed changes in standardized uptake value for prediction of pathologic response, PFS, and OS and pooled diagnostic accuracy and survival estimates across eligible studies ^[8]B2a. MRI-radiomics models have also been developed for disease-free and overall survival prediction in esophageal squamous cell carcinoma; one retrospective study used a 1-mm isotropic three-dimensional contrast-enhanced StarVIBE sequence and compared clinical-only, radiomics-only, and combined models using concordance indices and calibration curves ^[75]A1b. These approaches are prognostic or predictive investigations rather than established substitutes for outcome endpoints in radiation trials ^{[5]B2a[8]B2a[69]B2a[75]A1b}.

Local endoscopic outcomes relevant to early disease

For superficial neoplasia treated endoscopically, outcomes include complete and en bloc resection, procedure duration, complications, recurrence, and post-treatment stricture. A meta-analysis comparing endoscopic submucosal tunnel dissection with conventional endoscopic submucosal dissection evaluated these endpoints in early superficial upper-gastrointestinal lesions ^[77]B2a. In a multicenter randomized-trial dataset involving 223 patients with large superficial esophageal neoplasms, a post hoc comparison evaluated needle-type versus insulated-tip knives and included procedural difficulty and operator handover as outcomes ^[74]A1b. Extensive mucosal resection involving more than three-quarters of the esophageal circumference is associated with substantial stricture risk; a randomized trial compared intralesional steroid injection with oral prednisolone for stricture prevention after extensive endoscopic submucosal dissection, measuring dilation requirements, stricture rate, and stricture-resolution rate ^[71]A1b. These findings concern endoscopic local therapy and toxicity, not radiation-dose escalation ^{[71]A1b[74]A1b[77]B2a}.

Liquid-nitrogen spray cryotherapy is an approved tissue-ablation modality used in esophageal disease for more than 20 years. Practical optimization focuses on procedural safety, efficiency, technical success, and outcomes in esophageal malignancy, but the cited clinical-tips article does not provide comparative survival estimates against radiotherapy ^[82]. Similarly, endoscopic eradication therapy for Barrett’s esophagus and related neoplasia can eradicate neoplasia but carries greater harms and resource use than surveillance endoscopy; these outcomes apply primarily to early neoplasia and should not be extrapolated to locally advanced cancer requiring radiation management ^[68]A1c.

Non-oncologic and advanced-disease outcomes

Perioperative outcomes remain relevant when neoadjuvant chemoradiotherapy is followed by esophagectomy. A randomized study tested one-month low-molecular-weight-heparin thromboprophylaxis versus standard in-hospital prophylaxis after esophagectomy, using prothrombin fragment 1+2 at one month, venous thromboembolism, and mortality as endpoints ^[72]A1b. A randomized feasibility trial evaluated supervised versus home-based multimodal prehabilitation during neoadjuvant chemotherapy, with recruitment, retention, dropout, and functional outcomes as measures ^[73]C4. A randomized comparison of mediastinoscope-assisted and classic transhiatal esophagectomy assessed operative results in 62 patients ^[83]. Rare metastatic patterns, including small-bowel metastasis from esophageal squamous cell carcinoma, generally indicate advanced disease and may present with nonspecific abdominal symptoms; a systematic review summarized 23 reported cases, but these data are unsuitable for estimating routine radiation outcomes ^[86]. Finally, retrospective studies have explored associations between immune-related adverse events and long-term survival during immune-checkpoint-inhibitor combinations, and between dyslipidemia and outcomes during checkpoint inhibition; these associations are exploratory and do not establish radiation-response predictors ^[78]C4[87].

Part of the Esophageal Cancer family. Cross-cutting management is split across dedicated child pages:

• Esophageal Cancer , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
• Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
• Esophageal Cancer Systemic Therapy , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
• Esophageal Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
• Esophageal Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
• Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease

Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.